Doğan, Aslıhan ŞeydaPala, MukaddesYılmaz, Şenay GörücüBECEREN, AYFERKarabulut, AydınPolat, YalçınELÇIOGLU, HATICE KÜBRA2025-10-242025-10-2420252148-2373https://doi.org/10.14235/bas.galenos.2024.74429https://search.trdizin.gov.tr/tr/yayin/detay/1326372https://hdl.handle.net/20.500.12899/2208Objective: Diabetic cardiomyopathy (DCM) is characterized by complex pathophysiological events. miRNAs play a role in the DCM. In our study, the potential of miRNAs as a biomarker in the diagnosis and treatment of DCM was evaluated in the diabetes model induced by streptozotocin in rats. Methods: Therefore, miRNAs obtained from rat heart tissue were analyzed by microarray, and twelve miRNAs (rno-miR-200c-3p, rno-miR-129-5p, rno-miR-150-3p, rno-miR-3584-5p, rno-miR-34c-3p, rno-miR-342-3p, rno-miR-466b-3p, rno-miR-466c-3p, rno-miR-31a-3p, rno-miR-15b-5p, rno-miR-196b-3p, and rno-miR-208a-5p) with changed expression levels were validated by real-time polymerase chain reaction analysis. Results: As a result of the validation, it was determined that three miRNAs (rno-miR-15b-5p, rno-miR-196b-3p, and rno-miR-208a-5p) were downregulated, one miRNA (rno-miR-200c-3p) was upregulated (p<0.05). MiR-15b-5p, miR-196b-3p, miR-200c-3p, and miR-15b-5p are involved in the regulation of DCM, and the GRAP2 gene is one of the possible targets of these miRNAs. Conclusion: miR-200c-3p has diagnostic value and may be a biomarker candidate.eninfo:eu-repo/semantics/openAccessStreptozotocinbiomarkermiRNA expressionDiabetic cardiomyopathyArticle10.14235/bas.galenos.2024.7442913135441326372